Efalizumab in routine use: A clinical experience

British Journal of Dermatology

Volumn 156, Issue SUPPL. 2, 2007, Pages 1-6

  Selenko Gebauer, N ^a   Karlhofer, F ^a   Stingl, G ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

Author keywords

Efalizumab; Patient management; Psoriasis

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; ANTIPSORIASIS AGENT; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; METHOXSALEN; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTHRALGIA; ARTHRITIS; ARTICLE; BASAL CELL CARCINOMA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; GENERALIZED INFLAMMATORY FLARE; HISTOPLASMOSIS; HUMAN; INFECTION; LEUKOCYTOSIS; MENINGITIS; OUTPATIENT CARE; PAPULAR RASH; PATIENT COMPLIANCE; PHYSICIAN; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PSORIASIS; PUSTULOSIS PALMOPLANTARIS; PUVA; RASH; SKIN CANCER; SKIN DISEASE; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TOXOPLASMOSIS; TUBERCULOSIS; WOUND INFECTION;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11A; AUSTRIA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PATIENT EDUCATION; PATIENT SELECTION; PSORIASIS; RECURRENCE; SKIN; TREATMENT OUTCOME;

EID: 33947277466     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.07762.x     Document Type: Article

References (26)

1. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64 (Suppl. 2):ii18-23.
2. Griffiths CE, Iaccarino L, Naldi L et al. Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines. Clin Exp Rheumatol 2006; 24 (Suppl. 40):S72-8.
3. Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41:401-7.
4. Griffiths CE, Clark CM, Chalmers RJ et al. A systematic review of treatments for severe psoriasis. Health Technol Assess Rep 2000; 4: 1-125.
5. Jullien D, Prinz JC, Langley RG et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology 2004; 208:297-306.
6. Gordon KB, Papp KA, Hamilton TK et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290:3073-80.
7. Gottlieb AB, Gordon KB, Lebwohl MG et al. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol 2004; 3:614-24.
8. Gottlieb AB, Hamilton T, Caro I et al. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol. 2006; 54:S154-63.
9. Lebwohl M, Tyring SK, Hamilton TK et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349:2004-13.
10. Leonardi CL, Papp KA, Gordon KB et al. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. J Am Acad Dermatol 2005; 52:425-33.
11. Menter A, Gordon K, Carey W et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141:31-8.
12. Poulin Y, Papp KA, Carey W et al. A favourable benefit/risk ratio with efalizumab: a review of the clinical evidence. J Cutan Med Surg 2006; 9 (Suppl. 1):10-17.
13. Raptiva, Product Information, http://www.kompendium.ch
14. Raptiva EMEA approved product information, http://www.emea.-com
15. Carey W et al. Taper regimens in the management of patient discontinuing efalizumab therapy. Poster presented at the International Psoriasis Symposium. Canada: Toronto, 10-13 June 2004.
16. Menter A, Leonardi CL, Sterry W et al. Long-term management of plaque psoriasis with continuous efalizumab therapy. J Am Acad Dermatol 2006; 54 (Suppl. 1):S182-8.
17. Naldi L, Svensson A, Diepgen T et al. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol 2003; 120:738-41.
18. Heydendael VMR, Spuls P, Opmeer B et al. Methotrexate versus Cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349:658-65.
19. Langley RBG, Wayne PC, Rafal ES et al. Incidence of infections during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther 2005; 27:1317-28.
20. Dubertret L, Sterry W, Bos JD et al. Clinical experience aquired with the efalizumab (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 2006; 155:170-81.
21. Margolis D, Bilker W, Hennssy S et al. The risk of malignancy associated with psoriasis. Arch Dermatol 2001; 137:778-83.
22. Paul CF, Ho VC, McGeown C et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. Invest Dermatol 2003; 120:211-6.
23. McClure SL, Valentine J, Gordon KB. Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf 2002; 25:913-27.
24. Lindelöf B, Sigurgeirsson B, Tegner E et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol 1999; 141:108-12.
25. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and cyclosporine: nested cohort crossover study. Lancet 2001; 358:1042-5.
26. Scheinfeld N. Efalizumab: A Review of events reported during clinical trials and side effects. Expert Opin. Drug Saf 2006; 5:197-209.